Recent Developments in Antibody Derivatives Against Colorectal Cancer; a Review Publisher Pubmed



Ghani S^{1, 2, 3} ; Bahrami S² ; Rafiee B⁴ ; Eyvazi S⁵ ; Yarian F^{2, 3} ; Ahangarzadeh S⁶ ; Khalili S⁷ ; Shahzamani K⁸ ; Jafarisani M⁹ ; Bandehpour M^{2, 3} ; Kazemi B^{2, 3}
Source: Life Sciences Published:2021

Abstract

Colorectal cancer (CRC) is the fourth most common cause of cancer and mortality worldwide and is the third most common cancer in men and women. Surgery, radiotherapy, and chemotherapy are conventionally used for the treatment of colorectal cancer. However, these methods are associated with various side effects on normal cells. Thus, new studies are moving towards more effective and non-invasive methods for treatment of colorectal cancer. Targeted therapy of CRC is a promising new approach to enhance the efficiency and decrease the toxicity of the treatment. In targeted therapy of CRC, antibody fragments can directly inhibit tumor cell growth and proliferation. They also can act as an ideal carrier for targeted delivery of anticancer drugs. In the present study, the structure and function of different formats of antibody fragments, immune-targeted therapy of CRC using antibody fragments will be discussed. © 2020 Elsevier Inc.